The latest price target for IGC Pharma (AMEX:IGC) was reported by Alliance Global Partners on July 17, 2024. The analyst firm set a price target for $3.50 expecting IGC to rise to within 12 months (a possible 637.77% upside). 2 analyst firms have reported ratings in the last year.

The latest analyst rating for IGC Pharma (AMEX:IGC) was provided by Alliance Global Partners, and IGC Pharma initiated their buy rating.

There is no last upgrade for IGC Pharma

There is no last downgrade for IGC Pharma.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of IGC Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for IGC Pharma was filed on July 17, 2024 so you should expect the next rating to be made available sometime around July 17, 2025.

While ratings are subjective and will change, the latest IGC Pharma (IGC) rating was a initiated with a price target of $0.00 to $3.50. The current price IGC Pharma (IGC) is trading at is $0.47, which is within the analyst’s predicted range.